Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study

S L Gooskens1,14, R Furtwängler2,14, F Spreafico3, H van Tinteren4, J de Kraker*,5, G M Vujanic6, I Leuschner7, A Coulomb-L’Hermine8, J Godzinski9, G Schleiermacher10, S Stoneham11, C Bergeron12, K Pritchard-Jones13, N Graf2 and M M van den Heuvel-Eibrink*,1
1Department of Paediatric Haematology and Oncology, Erasmus MC – Sophia Children’s Hospital, Dr. Molewaterplein 60, 3015GJ Rotterdam, The Netherlands; 2Department of Paediatric Haematology and Oncology, Saarland University, Campus, 66123 Saarbrücken, Germany; 3Paediatric Oncology Unit, Department of Haematology and Paediatric Onco-Haematology, Fondazione IRCCS Instituto Nazionale dei Tumori, Via Giacomo Venezian,1, 20133 Milano, Italy; 4Department of Statistics, Netherlands Cancer Institute (NKI-AvL), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 5Department of Paediatric Haematology and Oncology, Academic Medical Center—Emma Children’s Hospital, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; 6Department of Pathology, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK; 7Institute of Pathology, University of Kiel, Christian-Albrechts-Platz 4, 24118 Kiel, Germany; 8Department of Pathology, Hopitaux Universitaires Est Parisien, Trouseau La Roche-Guyon, 26 Avenue du Docteur Arnold Netter, 75012 Paris, France; 9Department of Emergency Medicine, Medical University of Wrocław, and Department of Paediatric Surgery, Marcinik Hospital, Slezna 96, 53-111 Wrocław, Poland; 10Department of Paediatric Oncology and INSERM U830, Institut Curie, 26 Rue d’Ulm, 75005 Paris, France; 11Department of Paediatric and Adolescent Oncology, University College Hospital, 235 Euston Rd, London NW1 2BU, UK; 12Department of Paediatrics, Centre Lyon Berard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France and 13Molecular Haematology and Cancer Biology, Institute of Child Health, University College, Gower St, London WC1E 6BT, UK

Background: Clear cell sarcoma of the kidney (CCSK) is an uncommon paediatric renal tumour. Relapses occur in about 15% of the patients. Since detailed clinical information on relapsed CCSK is scarce, the current study aims to describe outcome of patients with relapsed CCSK treated according to recent European protocols.

Patients and methods: We analysed prospectively collected data of all CCSK patients who developed a relapse after complete remission at the end of primary treatment, entered onto SIOP and AIEOP trials between 1992 and 2012.

Results: Thirty-seven of 237 CCSK patients (16%) treated according to SIOP and AIEOP protocols developed a relapse. Median time from initial diagnosis to relapse was 17 months (range, 5.5 months - 6.6 years). Thirty-five out of thirty-seven relapses (95%) were metastatic; the most common sites of relapse were the brain (n=13), lungs (n=7) and bone (n=5). Relapse treatment consisted of chemotherapy (n=30), surgery (n=19) and/or radiotherapy (n=18), followed by high-dose chemotherapy and autologous bone marrow transplantation (ABMT) in 14 patients. Twenty-two out of thirty-seven patients (59%) achieved a second complete remission (CR); 15 of whom (68%) developed a second relapse. Five-year event-free survival (EFS) after relapse was 18% (95% CI: 4%–32%), and 5-year overall survival (OS) was 26% (95% CI: 10%–42%).

Conclusions: In this largest series of relapsed CCSK patients ever described, overall outcome is poor. Most relapses are metastatic and brain relapses are more common than previously recognised. Intensive treatment aiming for local control, followed by high dose chemotherapy and ABMT, seems to be of benefit to enhance survival. Novel development of targeted therapy is urgently required.

*Correspondence: Dr MM van den Heuvel-Eibrink; E-mail: m.vandenheuvel@erasmusmc.nl
14These authors contributed equally to this work.
*Deceased.

Received 31 January 2014; revised 17 April 2014; accepted 7 May 2014; published online 17 June 2014
© 2014 Cancer Research UK. All rights reserved 0007 – 0920/14
Clear cell sarcoma of the kidney (CCSK) is an uncommon type of childhood renal cancer (2%–5% of all primary renal tumours in children) that is observed most often in children under 3 years of age (Argani et al, 2000; Goossens et al, 2012).

With current intensive treatment schedules, including radiotherapy and multi-agent chemotherapy, outcome of CCSK has significantly improved (5-year event-free survival 75%–85%, 5-year overall survival 85%–90%) (Argani et al, 2000; Goossens et al, 2012, Furtwängler et al, 2013). Despite this improved survival, there is still a considerable relapse rate, especially in younger patients and patients with advanced stage disease (Argani et al, 2000; Seibel et al, 2006; Furtwängler et al, 2013).

Up until now, only three descriptive reports on clinical characteristics, treatment and outcome of relapsed CCSK have been published, including 11 patients in total (Table 1) (Kusumakumary et al, 1997; Yumura-Yagi et al, 1998; Radulescu et al, 2008). Therefore, data on clinical features of these patients are scarce and the contribution of chemotherapy, surgery, radiotherapy and high-dose chemotherapy followed by ABMT to optimal treatment of relapsed CCSK has not been established as yet. In addition, recent reports from the International Society for Pediatric Oncology (SIOP) and the National Wilms Tumor Study Group (NWTSG) have indicated that, following intensified upfront treatment, the pattern of relapses is changing with brain metastases now more common than the classical site of bone metastases in its original description as the 'bone metastasising renal tumour of childhood' (Marsden and Lawler, 1978; Furtwängler et al, 2005; Seibel et al, 2006).

This study aims to evaluate clinical characteristics, treatment and outcome of relapsed CCSK patients treated according to different national guideline for their patients included in the current analyses. Prospectively collected data on patient- and treatment characteristics as well as relapse- and survival data were retrieved from SIOP and AIEOP databases. Informed consent for participating in the studies had been obtained from patients and parents before treatment, according to national law and regulations. Ethical approval was obtained from medical ethical committees of all participating international centres.

### Patients and Methods

**Patients.** All patients with recurrent CCSK after complete remission at the end of primary treatment, registered and treated according to SIOP 93-01 (1993–2001), SIOP 2001 (2001–2011), AIEOP BNR-92 (1992–1998) and AIEOP WT-2003 (2003–ongoing) clinical trials, were included in the current analyses. Prospectively collected data on patient- and treatment characteristics as well as relapse- and survival data were retrieved from SIOP and AIEOP databases. Informed consent for participating in the studies had been obtained from patients and parents before treatment, according to national law and regulations. Ethical approval was obtained from medical ethical committees of all participating international centres.

**Treatment at initial diagnosis.** Patients were treated upfront according to study-specific guidelines (Supplementary Table 1). Patients entered onto SIOP 93-01 and SIOP 2001 studies were treated with pre-operative chemotherapy. Immediate tumour nephrectomy was performed in SIOP 93-01 and SIOP 2001 patients younger than 6 months or older than 18 years, and in patients treated according to AIEOP protocols unless the tumour was judged inoperable. The United Kingdom used a different national guideline for their patients included in the SIOP 2001 trial, including initial biopsy and intensified pre-operative chemotherapy if the biopsy revealed CCSK.

### Table 1. Reported relapsed CCSK patients

| Study                  | 
|-----------------------|
| Kusumakumary et al, 1997 | 1 | AV | 8.5y | Primary site | Palliative only | Yes | No | Yes | No | DOD 4m |
| Yumura-Yagi et al, 1998 | 2 | NWTS 3 | 10m | Bone | VP16, THP, CIS | No | Yes | Yes | IFO/MEL + BUS/THIO | NED 4.1y |
| Radulescu et al, 2008 | 8 | NWTS 5 | Median 25m (range 6–42m) | Brain (n = 6), brain and bone (n = 2) | 8/8 (ICE + / – other chemotherapeutic agents) | 7/8 (sCR n = 4) | 6/8 | 4/8 (BUS/MEL/THIO, BUS/TOPO/MEL, CARBO/THIO/TOPO, THIO/CYCLO + CARBO/MEL) | - 6 NED (median FU 2.6y) | - 1 DOD | - 1 Died of sepsis |
| Goossens et al, 2014 (Current study) | 37 | SIOP 93-01, AIEOP WT-2003 | Median 17m (range 15 – 13.6y) | Brain (n = 13), lungs (n = 7), bone (n = 5), primary site (n = 2), soft tissue (n = 1), extra-abdominal (n = 1), multiple (n = 8) | 30/37 (Table 4) | 19/37 (sCR n = 11) | 18/37 | 14/37 (Table 3) | - 10 NED (median FU 4.6y) | - 1 AWD 4.3y | - 22 DOD | - 2 Died of sepsis | - 1 Lost to follow-up | - 1 Unknown |

Abbreviations: AV = actinomycin/vincristine; AIEOP = Associazione Italiana Ematologia Oncologia Pediatrica; AWD = alive with disease; BUS = busulphan; CT = chemotherapy; CIS = cisplatin; CYCLO = cyclophosphamide; CARBO = carboplatin; DOD = dead of disease; FU = follow-up; HD-CT + ABMT = high-dose chemotherapy followed by autologous bone marrow transplantation; ICE = ifosfamide/carboplatin/etoposide; IFO = ifosfamide; m – month; MEL = melphalan; NED = no evidence of disease; NWTS = National Wilms Tumor Study; RT = radiotherapy; S = surgery; sCR = complete surgical remission; SIOP = International Society of Pediatric Oncology; THP = hydroxypropyladriamycin; THIO = thiopeta; TOPO = topotecan; UK-CCG = United Kingdom Children’s Cancer and Leukaemia Group; VP16 = etoposide; y = year.

aTime after date of initial diagnosis.

bTime after last treatment for relapse.
Pritchard-Jones et al, 2012). Administered post-operative treatment and applied radiotherapy per regimen is depicted in Supplementary Table 1.

**Histopathology.** All cases were centrally reviewed by panels of pathologists at time of nephrectomy. Tumours of SIOP trials were classified according to the SIOP Working Classification of Renal Tumours of Childhood and staged according to the SIOP 93-01 and SIOP 2001 trial criteria (Delemarre et al, 1996; Vujanic et al, 2002). Tumours of AIEOP trials were classified and staged according to NWTS criteria (Argani et al, 2000).

**Statistical analysis.** Statistical analysis was performed using the statistical software of SPSS (version 20.0) and GraphPad (version 5.01). Event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan–Meier method, together with corresponding 95% confidence intervals (CIs). EFS was calculated from date of relapse to occurrence of a subsequent relapse or death, and OS was calculated from date of relapse to death for any reason. Patients with neither a further relapse nor death were censored at the time of the last follow-up record.

### RESULTS

**Clinical features and treatment at primary diagnosis.** This study describes all 37 relapses that occurred in the 237 CCSK patients treated according to the SIOP 93-01 (n = 98), SIOP 2001 (n = 114) and AIEOP (n = 25) trials between 1992 and 2012. Clinical features and treatment of relapsed patients at initial diagnosis are depicted in Table 2. Forty-three percent of the patients presented with stage I and II disease, while the rest of the patients had more advanced disease stages.

Eighty-nine percent of the patients (n = 33) were treated with three or more drugs at initial diagnosis (Table 2). Twenty-four out of thirty-seven patients were treated with alkylating agents (that is, ifosfamide or cyclophosphamide); patients who were treated with cyclophosphamide (n = 10) had relapses located in the brain (n = 4), lungs (n = 2), bone (n = 1) and multiple sites (n = 3), while patients treated with ifosfamide (n = 13) had relapses located in the brain (n = 8), lungs (n = 3), bone (n = 1) and primary site (n = 1) (Supplementary Table 2).

Fourty-nine percent of the patients had been treated with radiotherapy at initial diagnosis. All four patients with a relapse located at the primary site had been treated upfront without local radiotherapy (3 stage I, 1 stage II) (Supplementary Table 2).

**Clinical features at relapse.** Median time from initial diagnosis to relapse was 17 months (range 5.5 months–6.6 years). Median age at the time of relapse was 42.5 months (range, 15 months–13.6 years). All patients younger than 12 months at initial diagnosis (n = 12) had a relapse ≤ 17 months after initial diagnosis. Sites of relapse are depicted in Table 3; most relapses were metastatic (n = 35) and the brain (n = 13), lungs (n = 7) and bone (n = 5) were the most common sites of relapse. Three patients with a relapse located in the brain died shortly after the occurrence of relapse; two of them died immediately because of intra-cerebral bleeding of the tumour and one patient died 23 days later after palliative treatment.

**Treatment at relapse.** No standard treatment guideline was available for relapsed CCSK, except in the United Kingdom where relapsed patients were treated according to the recommendations of the UKWR trial including carboplatin, etoposide and cyclophosphamide followed by high-dose melphalan (Hale et al, 2008) (Supplementary Table 3). Detailed data on treatment of relapse were not available in two patients, and three patients with a relapse located in the brain died shortly after detection of the relapse, before treatment could be started. Thirty out of thirty-seven patients (81%) were treated with different combinations of chemotherapy, in 19/37 patients (51%) surgical excision was performed (after biopsy confirming CCSK), 18/37 patients (49%) were treated with radiotherapy (median radiotherapy dose 27 Gy, range, 12–32 Gy) and 14/37 patients (38%) received subsequently high-dose chemotherapy and autologous bone marrow transplantation (ABMT) (Table 3 and Supplementary Table 3).

**Response to relapse treatment and outcome.** Median follow-up time after relapse was 19 months (range, 0–109 months). Twenty-two out of thirty-seven patients (59%) achieved a second CR after relapse treatment. Fifteen of these 22 patients (68%) developed a second relapse. Five-year EFS after relapse was 18% (95% CI: 0–46%).

| Table 2. Clinical features and treatment at initial diagnosis |
|-------------------------------------------------------------|
| **Clinical features** | **n (%)** |
| **Protocol** |  |
| SIOP 93-01 | 15 (41%) |
| SIOP 2001 | 18 (49%) |
| AIEOP 92 and AIEOP 2003 | 2 (5%) |
| **Gender** |  |
| Male | 24 (65%) |
| Female | 13 (35%) |
| **Age (months)** |  |
| Median | 16 months |
| Range | 2–143 months |
| **Stage** |  |
| I | 13 (35%) |
| II | 3 (8%) |
| III | 15 (41%) |
| IV | 5 (14%) (lungs 4, bone 1) |
| Unknown | 1 (3%) |
| **Initial treatment** |  |
| Immediate surgery | 4 (11%) |
| **Pre-operative chemotherapy** |  |
| AV | 27 (73%) |
| AVD | 5 (14%) |
| AVE | 1 (3%) |
| **Post-operative chemotherapy** |  |
| VCCD | 10 (27%) |
| EIVC | 8 (22%) |
| AVD | 8 (22%) |
| AVE | 3 (8%) |
| AVE + DIVC | 2 (5%) |
| No post-operative chemotherapy* | 6 (16%) |
| Other |  |
| **Radiotherapy** |  |
| Yes | 18 |
| No | 18 |
| NA | 1 |

Abbreviations: AV = α-actinomycin/vincristine; AVD = α-actinomycin/vincristine/doxorubicin; AVE = α-actinomycin/vincristine/epirubicin; EIVC = etoposide/ifosfamide/etoposide/cyclophosphamide/cisplatin; EIVC = etoposide/ifosfamide/etoposide/cyclophosphamide/cisplatin; NA = not available; VCCD = etoposide/cyclophosphamide/doxorubicin.

*No post-operative chemotherapy because of refusal by the parents.
and 5-year OS after relapse was 26% (95% CI: 10–42%) (Figures 1 and 2).

Nine out of thirty-seven relapsed patients remained in long-term second CR after a median follow-up time from date of relapse of 4.8 years (range, 1.2–9.0 years) (Table 3). One out of thirty-seven patients is currently alive with disease (second relapse in the brain, 4.3 years after his first relapse in the brain). Two out of thirty-seven patients were lost to follow-up, and in one patient outcome data were not available. Twenty-four out of thirty-seven relapsed patients (65%) died; causes of death were tumour progression (n = 22) or treatment-related mortality (n = 2) (patients died because of septic shock after one dose of topotecan and after one cycle of ICE (ifosfamide, carboplatin and etoposide), respectively).

The small number of the hereby described series of relapsed CCSK patients does not allow statistical analyses. In order to get some insight in clinical variables and successful treatments, we summarised characteristics of patients that achieved a second CR.
separate from patients that did not reach second complete CR. We only included patients that completed intended relapse treatment (n = 27) (Table 4). Patients who died immediately after diagnosis (n = 3), patients who died early of treatment-related toxicity (n = 2) patients who are alive with disease (n = 1) and patients who had incomplete follow-up data (n = 4) were not included in this comparison. Patients who achieved a second CR (n = 21) were compared with patients who did not achieve a second CR (n = 7) (Table 4). In 11/21 second CR patients complete surgical resection was performed, whereas no complete surgical resection was performed in the 7 patients who did not achieve second CR. High-dose chemotherapy courses were applied in 13/21 second CR patients, whereas high-dose chemotherapy was applied in 1/7 patients who did not achieve second CR (Table 4). Subsequently, we focused on patients who achieved a second CR (n = 20). Of this group, 11 patients died of disease after second CR (median time to death 32 months) and 9 patients remained in long-term second CR (median follow up time 58 months) after relapse treatment; clinical variables and administered treatment of these subgroups are depicted in Table 4.

Treatment outcome according to site of relapse is described in Table 3. Thirteen out of thirty-seven patients had a relapse located in the brain only, of whom four patients survived after relapse treatment. One patient who survived after relapse treatment recently suffered from a new (very late) recurrence in the brain (Table 3). Two patients with a relapse located in the brain died immediately after recognition of recurrence because of intratumoural bleeding, and one patient died shortly after diagnosis of treatment-related mortality after surgery and one dose of topotecan (Table 3). Seven out of thirty-seven patients had a relapse located in the lungs only, of which one patient survived after relapse treatment (Table 3). Isolated bone metastases occurred in 5 out of 37 patients, of which three patients survived after relapse treatment (Table 3). Two out of thirty-seven patients had a local relapse, of which one patient is in persistent second CR.

Table 4. Clinical variables of relapsed patients

|                                | 2nd CR (n = 21)a                    | DOD after 2nd CR (n = 11) | No 2nd CR (n = 7) |
|--------------------------------|------------------------------------|---------------------------|------------------|
| **Median time to relapse (range)b** |                                    |                           |                  |
|                                | 22 months (13–79 months)           | 16 months (14–30 months) | 16 months (9–38 months) |
| **Median follow-up time (range)c** |                                    |                           |                  |
|                                | 54 months (14–109 months)          | 32 months (range 10–45 months) | 14 months (range 8–29 months) |
| **Median age at initial diagnosis (range)** |                                    |                           |                  |
|                                | 14 months (7–83 months)            | 22 months (2–143 months)  | 76 months (4–141 months) |
| **Site of relapse**            |                                    |                           |                  |
| Brain:                          | 4 (40%)                            | Brain:                    | Brain:           |
| Bone:                           | 2 (20%)                            | 3 (27%)                   | 1 (9%)           |
| Multiple:                       | 1 (10%)                            | Multiple:                 | Multiple:        |
| Soft tissue:                    | 1 (10%)                            | 2 (18%)                   | 1 (10%)          |
| Lungs:                          | 1 (10%)                            | Brain:                    | Brain:           |
| Primary site:                   | 1 (10%)                            | 1 (9%)                    | 1 (14%)          |
| **ICE chemotherapy**           |                                    |                           |                  |
| ICE:                            | 5 (50%)                            | ICE:                      | ICE:             |
| No ICE:                         | 5 (50%)                            | No ICE:                   | No ICE:          |
| **Surgery**                    |                                    |                           |                  |
| Surgery:                        |                                    |                           |                  |
| Surgery:                        | 8 (80%)                            | Surgery:                  | Surgery:         |
| sCR:                            | 6 (60%)                            | sCR:                      | 2 (29%)          |
| No sCR:                         | 2 (20%)                            | No sCR:                   | No sCR:          |
| No surgery:                     | 2 (20%)                            | No surgery:               | No surgery:      |
| **Radiotherapy**               |                                    |                           |                  |
| Radiotherapy:                   | 8 (80%)                            | Radiotherapy:             | Radiotherapy:    |
| No radiotherapy:                | 2 (20%)                            | 5 (45%)                   | 4 (57%)          |
| **HD-CT + ABMT**               |                                    |                           |                  |
| HD-CT:                          | 7 (70%)                            | HD-CT:                    | HD-CT:           |
| No HD-CT:                       | 3 (30%)                            | 6 (55%)                   | 1 (14%)          |
| Abbreviations: ICE = ifosfamide/carboplatin/etoposide; HD-SCT + ABMT = high-dose chemotherapy followed by autologous bone marrow transplantation; 2nd CR = second complete remission; sCR = surgical complete remission.  

One additional patient reached 2nd CR, but recently developed a 2nd relapse and is currently alive with disease.  

Median time from initial diagnosis until relapse.

Abbreviations: ICE = ifosfamide/carboplatin/etoposide; HD-SCT + ABMT = high-dose chemotherapy followed by autologous bone marrow transplantation; 2nd CR = second complete remission; sCR = surgical complete remission.

One additional patient reached 2nd CR, but recently developed a 2nd relapse and is currently alive with disease.

Median time from initial diagnosis until relapse.

Median time from first relapse until death or last date of follow-up.
Eight out of thirty-seven patients had relapses located at multiple sites, of which only one patient with relapses in the bone and brain is in persistent second CR after 4, 8 years of follow-up (Table 3). Two patients with disseminated disease were lost to follow-up shortly after diagnosis of relapse, and one patient with a relapse located at primary site and paravertebral died due to treatment-related mortality after one cycle of ICE chemotherapy (Table 3).

DISCUSSION

This study reports on clinical characteristics, treatment and outcome of all children with relapsed CCSK after complete remission at the end of primary treatment, entered onto SIOP 93-01, SIOP 2001 and AIEOP trials. It represents the largest series of relapsed CCSK patients described so far (Table 1). We realise this is a descriptive study, nevertheless we consider it valuable to describe our series as data on treatment and outcome of relapsed CCSK patients are very scarce. This study reveals that outcome of relapsed CCSK patients is poor, that brain seems to have surpassed the bone as most common site of relapse and that intensive treatment, including chemotherapy as well as achieving local control by complete surgery and/or radiotherapy, is necessary to salvage CCSK patients.

We have demonstrated previously that survival rates are disappointing for younger children with CCSK (Furtwängler et al., 2013). Consequently, 32% of the relapsed patients were infants at the time of initial diagnosis, and the median age at the time of diagnosis was 16 months for relapsed CCSK patients, compared with a median age of 31 months of all CCSK patients described in a previous study (Furtwängler et al., 2013).

Our data show that relapses occur relatively late. This seems to be characteristic for CCSK according to earlier reports that describe occurrence of recurrences up to 8 years after initial diagnosis (Kusumakumary et al., 1997). Green et al. (1994) reported that 30% of relapses in NWTS 1-3 patients occurred more than 2 years after diagnosis. In the most recent North-American National Wilms Tumor Study (NWTS) trial, only 1 out of 21 relapses (5%) occurred beyond 3 years after diagnosis (Seibel et al., 2006). In our series, nine cases (24%) relapsed later than 2 years after initial diagnosis and four of these cases (11%) relapsed even more than 3 years after initial diagnosis (up to 6.6 years after initial diagnosis). Patients younger than 12 months at initial diagnosis all relapsed within 17 months after initial diagnosis, which might imply that the biological behaviour of CCSK is more aggressive in young children. Altogether this indicates that children with CCSK need extended and more intensive follow-up for detection of relapses than, for instance, patients with nephroblastoma. The late recurrences in CCSK are remarkable as it fundamentally is an aggressive tumour, illustrated by the fact that outcome on average is poor.

The pattern of relapse included distant metastases in more than 95% of our patients, similar to earlier reports (Argani et al., 2000). The most frequent locations of relapse were the brain, lungs and bone. Previous reports showed bone to be the most frequent site of CCSK recurrence, for which reason CCSK was initially referred to as ‘bone metastasising tumour of the kidney’ (Marsden and Lawler, 1978; Green et al., 1994). Bone is still the most common site of metastases at initial diagnosis, but interestingly, according to our study and previous studies, the brain seems to have surpassed the bone as the most common site of CCSK recurrence (Furtwängler et al., 2005; Seibel et al., 2006). This indicates that the brain might be a sanctuary for cells that are protected from intensive chemotherapy that patients currently receive. One would expect the highest rate of brain relapses in the group of patients less adequately treated with central nervous system (CNS)-penetrating drugs (vincristine, ifosfamide, carboplatin) (Yule et al., 1997). In Europe, brain relapses occurred in 8 out of 15 cases (53%) treated with ifosfamide (SIOP 93-01, AIEOP CNR-92; AIEOP WT-2003) versus 6 out of 15 cases (40%) treated with cyclophosphamide (SIOP 2001). All these cases, either treated with ifosfamide or cyclophosphamide were also treated with carboplatin. In NWTS-5, 11 out of 23 (52%) relapses occurred in the brain; these patients were treated with vincristine, doxorubicin, cyclophosphamide and etoposide, but without carboplatin and ifosfamide (Seibel et al., 2006). This indicates that other factors than CNS penetration of the applied agents may have a role in this preference location of CCSK relapses. Radulescu et al. (2008) describe eight NWTS CCSK patients with a relapse in the brain, all treated with a variable number of courses of ICE (ifosfamide, carboplatin, etoposide); 7 out of 8 patients achieved a second complete response, and 1 out of 8 patients died from complications of bacteraemia (Radulescu et al., 2008). In our series, 5 out of 13 patients with an isolated relapse in the brain were treated with ICE chemotherapy, of which three patients achieved a long-term complete response. This may indicate that treatment including ICE is promising for patients with a relapse in the brain, although we currently have no data on the influence of other factors like type of upfront treatment and hence, development of resistance. As the brain is the most common site of relapse, a logical consequence would be to include MRI of the brain in follow-up protocols of CCSK patients. However, relapses occur in only 16% of all CCSK patients, and 41% of these relapses are located in the brain. This indicates that all CCSK patients have to be screened by MRI of the brain during follow-up in order to detect brain relapses in only 7% of these patients. Besides practical objections such as anaesthesia in young children, this does not seem to be cost-effective. Nevertheless, brain MRI seems to be of value in case of suspicion of a brain relapse in an individual CCSK patient and as work-up for patients with a relapse detected elsewhere.

As the number of relapsed patients reported is too small to draw conclusions regarding the contributions of chemotherapy, high-dose chemotherapy followed by stem-cell transplantation, radiotherapy and surgery to the treatment of recurrent CCSK, no standard treatment guidelines are available for this patient group (Table 1).

More than half of the patients achieved a second CR after relapse treatment, but 68% of these patients subsequently developed a second relapse, indicating that consolidation of a second CR seems to be a challenge in relapsed CCSK patients. Intensive treatment, including chemotherapy as well as achieving local control by complete surgery (where possible) and/or radiotherapy, seems to enhance consolidation of second CR. Summarising our study and previous reports, in total 24 relapsed CCSK patients received high-dose chemotherapy followed by ABMT, of which 12 patients (50%) were alive without disease after a median follow-up of 52 months (range, 9–103 months) (Kullendorff and Bekassy, 1997; Pein et al., 1998; Yumura-Yagi et al., 1998; Radulescu et al., 2008; Furtwängler et al., 2013). This seems to be promising, although it should be emphasised that this high-dose chemotherapy is mostly applied in a selected group of patients who already achieved a second CR. In addition, high-dose chemotherapy followed by ABMT may cause treatment-related direct and late toxicity and needs to be weighed against the risk of disease-related mortality (Radulescu et al., 2008).

As treatment options for relapsed CCSK are limited and survival is poor, development of new targeted therapies based on biological characteristics of CCSK is necessary to improve survival of these children. Although the molecular background of CCSK is poorly understood, a few genetic aberrations have been described, that is, upregulation of the Sonic hedgehog signalling pathway and the PI3K/Akt signalling pathway and EGFR gene amplification and mutation (Cutschli et al., 2005; Little et al., 2007). In addition, a recurrent translocation of chromosome 10 and chromosome 17
has been described, including YWHAE and FAM22 genes (O’Meara et al, 2012). These molecular changes might be possible targets for therapy for early-phase trials.

For other sarcomas in children, new chemotherapeutic agents, such as irinotecan and temozolomide, are currently being studied in clinical trials (Raciborska et al, 2013). So far, it is unknown whether the biological character of these sarcomas is comparable to that of CCSK and whether these drugs are of any value for CCSK.

In conclusion, this largest series of relapsed CCSK patients ever described shows that outcome of relapsed CCSK patients is poor. Relapses tend to occur late, so extensive follow-up is desirable. Nearly all relapses are metastatic and the brain seems to have surpassed the bone as the most common site of relapse. Intensive treatment aiming for local control followed by high-dose chemotherapy and ABMT seems to be of benefit to enhance survival. International collaboration to develop new targeted therapies based on biological characteristics of CCSK is warranted to improve survival of CCSK patients that suffer from a relapse.

ACKNOWLEDGEMENTS

We would like to thank all participating SIOP and AIEOP centres. This work was supported by the Pediatric Oncology Center Society for Research (KOCHR), Rotterdam, The Netherlands, by the DaDa foundation, Nieuwerkerk aan den Ijssel, The Netherlands, and the Deutsche Krebshilfe, Germany (Grant No: 50-2709-Gr2).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Argani P, Perlman EJ, Breslow NE, Browning NG, Green DM, D’Angio GJ, Beckwith JB (2000) Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms’ Tumor Study Group Pathology Center. Am J Surg Pathol 24: 4–18.

Cutcliffe C, Kelsey D, Huang C, Zeng Y, Walterhouse D, Perlman EJ (2005) Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 11: 7986–7994.

Delemarre JF, Sandstedt B, Harms D, Boccon-Gibod L, Vujanic GM (1996) The new SIOP (Stockholm) working classification of renal tumours of childhood. International Society of Paediatric Oncology. Med Pediatr Oncol 26: 145–146.

Furtwängler R, Reinhard N, Beier R (2005) Clear-cell sarcoma (CCSK) of the kidney - results of the SIOP 93-01/GPOH trial. Pediatr Blood Cancer 45: 423 (abstract).

Furtwängler R, Gooskens SL, van Tinteren H, de Kraker J, Schleiermacher G, Bergeron C, de Camargo B, Acha T, Gozdzinski J, Sandstedt B, Leuschner I, Vujanic GM, Pieters R, Graf N, van den Heuvel-Eibrink MM (2013) Clear Cell Sarcomas of the Kidney (CCSK) registered on SIOP 93-61 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group. Eur J Cancer 49: 3497–3506.

Gooskens SL, Furtwängler R, Vujanic GM, Dome JS, Graf N, van den Heuvel-Eibrink MM (2012) Clear cell sarcoma of the kidney: a review. Eur J Cancer 48: 2219–2226.

Green DM, Breslow NE, Beckwith JB, Moksness J, Finkenstein JZ, D’Angio GJ (1994) Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 12: 2132–2137.

Hale JP, Hobson R, Moroz V, Sartori P (2008) Results of UK Children’s Cancer and Leukaemia Group (CCLG) protocol for relapsed Wilms tumour (UKWR): unified relapse strategy improves outcome. Proceedings of the 40th Meeting of International Society of Paediatric Oncology 62: O154 (abstract).

Kullendorf CM, Bekassy AN (1997) Salvage treatment of relapsing Wilms’ tumour by autologous bone marrow transplantation. Eur J Pediatr Surg 7: 177–179.

Kusumakumary P, Chellam VG, Rojymon J, Hariranan S, Kirshnan NM (1997) Late recurrence of clear cell sarcoma of the kidney. Med Pediatr Oncol 28: 355–357.

Little SE, Bad DA, Rodriguez-Pinilla M, Natrajan R, Messahel B, Pritchard-Jones K, Vujanic GM, Reis-Filho JS, Jones C (2007) Multifaceted dysregulation of the epithelial growth factor receptor pathway in clear cell sarcoma of the kidney. Clin Cancer Res 13: 4360–4364.

Marsden HB, Lawler W (1978) Bone-metastasizing renal tumour of childhood. Br J Cancer 38: 437–441.

Mitchell C, Pritchard-Jones K, Shannon R, Hutton C, Stevens S, Machin D, Imeson J, Kelsey A, Vujanic GM, Gormall P, Walker J, Taylor R, Sartori P, Hale J, Levitt G, Messahel B, Middleton H, Grundy R, Pritchard J (2006) Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms’ tumour: results of a randomised trial (UKW3) by the UK Children’s Cancer Study Group. Eur J Cancer 42: 2554–2562.

O’Meara E, Stack D, Lee CH, Garvin AJ, Morris T, Argani P, Han JS, Karlsson J, Gisselson D, Leuschner I, Gessler M, Graf N, Felder JA, O’Sullivan MJ (2012) Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of the kidney. J Pathol 227: 72–80.

Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP, Philip T, Bergeron C, Baranzelli MC, Thyss A, Stephan JL, Bostard P, Gentet JC, Zucker JM, Tournade MF, Hartmann O (1998) High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms’ tumor: a French Society of Pediatric Oncology study. J Clin Oncol 16: 3295–3301.

Pritchard-Jones K, Moroz V, Vujanic G, Powis M, Walker J, Messahel B, Hobson R, Levitt G, Kelsey A, Mitchell C (2012) Treatment and outcome of Wilms’ tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol 23: 2457–2463.

Raciborska A, Bilksa K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczynska K, Rogowska E, Rodriguez-Galindo C, Wozniak W (2013) Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer 60: 1612–1615.

Radulescu VC, Garrard M, Moertel C, Grundy PE, Mathias L, Feusner J, Diller L, Dome JS (2008) Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatr Blood Cancer 50: 246–249.

Reis-Filho JS, Jones C, Vujanic GM, Sandstedt B, Leuschner I, Gessler M, Graf N, van den Heuvel-Eibrink MM, Pieters R, Graf N, van den Heuvel-Eibrink MM (2013) Clear Cell Sarcomas of the Kidney (CCSK) registered on SIOP 93-61 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group. Eur J Cancer 49: 3497–3506.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)